Farmington Hills, MI – According to filings with the U.S. Securities and Exchange Commission, Ocuphire Pharma is raising $21,150,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Mina Sooch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ocuphire Pharma

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Our pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications.

To learn more about Ocuphire Pharma, visit http://ocuphire.com/

Contact:
Mina Sooch, President and Chief Executive Officer
248-681-9815
msooch@ocuphire.com
https://www.linkedin.com/in/mina-sooch-a7120/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved